Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease
Read more at prnewswire.comSelecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here